SG11202113053RA - Methods of otoprotection against platinum-based antineoplastic agents - Google Patents

Methods of otoprotection against platinum-based antineoplastic agents

Info

Publication number
SG11202113053RA
SG11202113053RA SG11202113053RA SG11202113053RA SG11202113053RA SG 11202113053R A SG11202113053R A SG 11202113053RA SG 11202113053R A SG11202113053R A SG 11202113053RA SG 11202113053R A SG11202113053R A SG 11202113053RA SG 11202113053R A SG11202113053R A SG 11202113053RA
Authority
SG
Singapore
Prior art keywords
otoprotection
methods
antineoplastic agents
based antineoplastic
against platinum
Prior art date
Application number
SG11202113053RA
Other languages
English (en)
Inventor
John Lee
John Soglia
Qi-Ying Hu
Fuxin Shi
Original Assignee
Decibel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/427,567 external-priority patent/US10813947B1/en
Application filed by Decibel Therapeutics Inc filed Critical Decibel Therapeutics Inc
Publication of SG11202113053RA publication Critical patent/SG11202113053RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0046Ear
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202113053RA 2019-05-31 2020-05-29 Methods of otoprotection against platinum-based antineoplastic agents SG11202113053RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/427,567 US10813947B1 (en) 2019-05-31 2019-05-31 Methods of otoprotection against platinum-based antineoplastic agents
US201962886865P 2019-08-14 2019-08-14
PCT/US2020/035271 WO2020243536A1 (en) 2019-05-31 2020-05-29 Methods of otoprotection against platinum-based antineoplastic agents

Publications (1)

Publication Number Publication Date
SG11202113053RA true SG11202113053RA (en) 2021-12-30

Family

ID=73553934

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202113053RA SG11202113053RA (en) 2019-05-31 2020-05-29 Methods of otoprotection against platinum-based antineoplastic agents

Country Status (11)

Country Link
EP (1) EP3975722A4 (es)
JP (1) JP2022534617A (es)
KR (1) KR20220047217A (es)
CN (1) CN114302647A (es)
AU (1) AU2020284122A1 (es)
BR (1) BR112021023684A2 (es)
CA (1) CA3142153A1 (es)
IL (1) IL288532A (es)
MX (1) MX2021014447A (es)
SG (1) SG11202113053RA (es)
WO (1) WO2020243536A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0811175D0 (en) * 2008-06-18 2008-07-23 Prendergast Patrick T Anti-tumour compositions and methods
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
CA2767168C (en) * 2009-07-08 2019-04-09 Hope Medical Enterprises, Inc. D.B.A. Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
US10596190B2 (en) * 2017-11-29 2020-03-24 Oregon Health & Science University Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
EP3986423A1 (en) * 2019-06-19 2022-04-27 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Sodium thiosulfate gel for preventing or reducing hearing loss

Also Published As

Publication number Publication date
EP3975722A1 (en) 2022-04-06
MX2021014447A (es) 2022-02-11
BR112021023684A2 (pt) 2022-04-12
WO2020243536A1 (en) 2020-12-03
CA3142153A1 (en) 2020-12-03
CN114302647A (zh) 2022-04-08
KR20220047217A (ko) 2022-04-15
IL288532A (en) 2022-01-01
EP3975722A4 (en) 2023-02-08
JP2022534617A (ja) 2022-08-02
AU2020284122A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
GB201814169D0 (en) Blockchain autonoumous agents
GB201801614D0 (en) Formulation
PL3873245T3 (pl) Formulacja ulegająca aerozolowaniu
IL290692A (en) Salt
IL289197A (en) History of 2-hydroxycycloalkane-1-carbamoyl
IL282589A (en) Aerosol formulation
IL293885A (en) A computer-implemented fluid handling protocol
IL290815A (en) History of alpha-d-galactopyranoside
IL284688A (en) formulation
GB2570524B (en) Fluency Aid
IL290525A (en) Antimalarial agents
GB201807312D0 (en) Formulation
IL288532A (en) Methods of self-defense against platinum-based antiplastic agents
GB201913232D0 (en) Aerosolisable formulation
MY174415A (en) Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof
PL3800215T3 (pl) Środek dyspergujący
GB2587402B (en) Formulation
ZA202103578B (en) Dna-cutting agent
ZA202103582B (en) Dna-cutting agent
GB201916493D0 (en) Firewall
GB2611435B (en) Well insert
GB2597022B (en) Well insert
GB2570736B (en) Fluency aid
GB2570735B (en) Fluency aid
GB2570734B (en) Fluency Aid